Effectiveness of anti-PD-1 for hepatocellular carcinoma - Authors' reply
Lancet Oncol
.
2020 Jun;21(6):e294.
doi: 10.1016/S1470-2045(20)30285-0.
Authors
Shukui Qin
1
,
Zhenggang Ren
2
,
Zhiqiang Meng
3
,
Zhendong Chen
4
,
Xiaoli Chai
5
Affiliations
1
Cancer Centre of Jinling Hospital, Nanjing 210002, China. Electronic address: qinsk@csco.org.cn.
2
Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
3
Minimally Invasive Therapy Center, Fudan University Shanghai Cancer Center, Shanghai, China.
4
Department of Medical Oncology, Second Hospital of Anhui Medical University, Hefei, China.
5
Department of Intervention, Hunan Cancer Hospital, Changsha, China.
PMID:
32502447
DOI:
10.1016/S1470-2045(20)30285-0
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal, Humanized
Carcinoma, Hepatocellular*
Humans
Liver Neoplasms*
Research Design
Substances
Antibodies, Monoclonal, Humanized
camrelizumab